U.S. Markets open in 34 hrs, 45 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,496.57 | 49.91 | 0.44% |
| NASDAQ | 2,282.78 | -29.52 | -1.28% |
| S&P 500 | 1,260.68 | 0.36 | 0.03% |
| Day Low 03:56 PM EDT | 3.70 | |
|---|---|---|
| Day High 10:51 AM EDT | 3.99 |
|
| Range | 0.29 | |
| Volume | 913,387 | |
| 30-Day Avg. Vol. | 574,000 |
|
| Difference | 59.13% | |
| Market Cap. | 289.02 M | |
| Change | -12.46 M | |
| Shares Out. | 77.9 M | |
| Percent Traded | 1.17% | |
| Revenue | 7.62 M | |
| Earnings | -45.77 M | |
| EPS (TTM) | -0.76 |
| 52-Wk Low 7/7/08 | 3.14 | |
|---|---|---|
| 52-Wk High 10/10/07 | 8.30 |
|
| Range | 5.16 | |
| Prev. Close 7/17/08 | 3.87 | |
| Today's Open | 3.90 | |
| Change | 0.78% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 1.7539 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | — |
Not far from the center of the controversy over human embryonic stem cell (hESC) research is Geron. The company hopes to parlay its work into viable therapies for various diseases and conditions. It is ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.177 12/31/07 | -0.22 12/31/07 |
-0.043
Missed
|
| Last Quarter | -0.183 3/31/08 | -0.18 3/31/08 |
0.003
Beat
|
| Quarterly - 03/31/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 1.69 M | 7.62 M |
| Gross Profit | -669,000.00 | 5.96 M |
| Operating Income | -15.95 M | -62.84 M |
| Net Income | -13.67 M | -45.78 M |
Real-Time Quote
